An Official Website of the United States Government
Company Information:
Name:
NATURE TECHNOLOGY CORPORATION
Address:
4701 INNOVATION DRIVE
LINCOLN, NE 68521-
LINCOLN, NE 68521-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
GENE SELF ASSEMBLY TECHNOLOGY
Award Year / Program / Phase:
1998 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Zink, Mary A
Award Amount:
$139,700.00
Promoter Rescue Vectors
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Clague P. Hodgson
Award Amount:
$142,017.00
Abstract:
DESCRIPTION (provided by applicant): Mouse VL30 (retrotransposon) long terminal repeats (LTRs) are a potential source of tissue-specific transcriptional promoters that can be used to deliver and express therapeutic genes in humans. Such vectors are badly needed, because the current retroviral… More
Chimeric enzyme for host nucleic acid autohydrolysis
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James A. Williams
Award Amount:
$143,800.00
Abstract:
DESCRIPTION (provided by applicant):
DNA vaccines and gene medicines are emerging as an important new class of pharmaceuticals that are derived from bacterial plasmids. For use in humans, plasmid DNA should be essentially free from bacterial genomic DNA and RNA, protein and endotoxin. The… More
Antisense inhibitors for enhanced plasmid production
Award Year / Program / Phase:
2005 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Jim Williams
Award Amount:
$136,195.00
Abstract:
DESCRIPTION (provided by applicant): Large scale manufacture of plasmid DNA is becoming increasingly important as the next generation of biotechnology products (gene medicines and DNA vaccines) make their way into clinical trials, and eventually into the pharmaceutical marketplace. Although… More
Chimeric enzyme for nucleic acid autohydrolysis
Award Year / Program / Phase:
2006 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Jim Williams
Award Amount:
$819,371.00
Abstract:
DESCRIPTION (provided by applicant): DNA vaccines and gene medicines, derived from bacterial plasmids, are emerging as an important new class of pharmaceuticals. DNA molecules made strictly by rational design allows the manufacturer to bypass years of development for the production of efficacious… More
eukaryotic expression vectors resistant to transgene silencing
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James Williams
Award Amount:
$145,542.00
Abstract:
DESCRIPTION (provided by applicant): Eukaryotic expression vectors are utilized for various biomedical applications including protein production, gene therapy and gene vaccination. A key barrier is that expression vectors undergo promoter inactivation (sil
encing) over time. This lack of sustained… More
Rapid deployment DNA vaccine for pandemic influenza
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James Williams
Award Amount:
$207,016.00
Abstract:
DESCRIPTION (provided by applicant): DNA-only vaccination would significantly enhance the rapid deployment utility of DNA vaccines for pandemic application (development times for DNA vaccines are significantly shorter than those for protein or viral vector
systems). The overall goal of this project… More
eukaryotic expression vectors resistant to transgene silencing
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
James Williams – 402-472-6530
Award Amount:
$920,664.00
Abstract:
DESCRIPTION (provided by applicant): Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented commercialization of plasmid-based therapies for human health applications. Previous innovations such as electroporation (EP)increased transgene expression through more… More